arrow
S

Siow Ming Lee

university college london hospitals nhs foundation trust
H指数:60
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study

非小细胞肺癌患者发生严重免疫检查点抑制剂毒性的预测因素与结局:一项英国多中心真实世界研究

Cancers
IF4.4
2026-03-030
OAAI
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study

简要报告:IPSOS III期研究中非小细胞肺癌铂类不适用性的事后验证

2025-07-220
PRE
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial☆

羟氯喹联合铂类双药化疗作为广泛期小细胞肺癌的一线治疗(研究15):一项随机II期多中心试验☆

2025-01-011
PRE
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

基于人工智能的模型ANORAK改善肺腺癌的组织病理学分级

2024-01-102
OAAI
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

一线阿特珠单抗单药治疗与单药化疗治疗不适合含铂方案 (IPSOS) 治疗的非小细胞肺癌患者: 一项3期,全球,多中心,开放标签,随机对照研究

LANCET
IF88.5
2023-08-0155
PRE
Body composition and lung cancer-associated cachexia in TRACERx

TRACERx中的身体成分和肺癌相关的恶病质

2023-04-1233
OAAI
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

TRACERx中肺腺癌形态学的进化特征

2023-04-1231
OAAI
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

新型冠状病毒肺炎: 第三剂加强疫苗对癌症患者突破性冠状病毒感染,住院和死亡的有效性: 一项基于人群的研究

2022-11-0136
OAAI
IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
2022-09-0121
OAAI
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

奥希替尼治疗未治疗、EGFR突变的晚期NSCLC的总生存期

2020-01-021.8K
OAAI
A phase I study of adoptive immunotherapy for ROR1+advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)

ROR1晚期三阴性乳腺癌 (TNBC) 的过继免疫治疗的I期研究,其中定义了表达ROR1-specific嵌合抗原受体 (ROR1-CAR) 的自体T细胞亚群

2019-02-1522
PRE
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

奥希替尼治疗未经治疗的EGFR突变的晚期非小细胞肺癌

2018-01-113.7K
OA